Dr. Reddy’s Laboratories (NYSE:RDY) announced Wednesday the first-to-market launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution, 0.7%, providing a lower-cost generic equivalent to Alcon’s Extra Strength Pataday® Once-Daily Relief.
Emergent BioSolutions (NYSE:EBS) received FDA approval Wednesday for a redesigned, compact carrying case for its over-the-counter (OTC) NARCAN® Nasal Spray, a move aimed at overcoming the "stigma of carrying" that has long hampered community-level overdose responses.
NRx Pharmaceuticals (NASDAQ:NRXP) achieved a pivotal regulatory milestone Wednesday, announcing the submission of a massive real-world dataset to the U.S. Food and Drug Administration (FDA) to support the accelerated approval of NRX-100, its proprietary preservative-free ketamine.
HUTCHMED (China) (NASDAQ:HCM) and partner AstraZeneca (NYSE:AZN) reached a major scientific milestone Wednesday with the publication of full Phase III SACHI trial results in The Lancet.
SEALSQ Corp (NASDAQ:LAES), the semiconductor and post-quantum cryptography subsidiary of WISeKey (NASDAQ:WKEY), announced Wednesday it has entered a non-binding Memorandum of Understanding (MOU) to potentially acquire a majority stake in QUOBLY, a Grenoble-based pioneer in silicon-based quantum computing.
AstraZeneca (NASDAQ:AZN) announced Tuesday at the J.P. Morgan Healthcare Conference that it has acquired Boston-based Modella AI, marking the first time a major pharmaceutical company has fully absorbed a specialized artificial intelligence firm.
ImmunityBio (NASDAQ:IBRX) announced positive results Tuesday from its ANKTIVA® clinical program, signaling a potential paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC) for patients who have exhausted standard-of-care options.
AudioEye (NASDAQ:AEYE) announced Tuesday its 40th consecutive period of record revenue, signaling that the global push for digital accessibility continues to fuel the company’s expansion.
BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.
Fortress Biotech Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, secured a historic regulatory victory Tuesday as the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate) as the first-ever treatment for Menkes disease.
NeuroPace (NASDAQ:NPCE) crossed a major financial threshold in 2025, reporting preliminary full-year revenue of approximately $100 million as its brain-responsive neurostimulation technology gains traction as a standard of care for drug-resistant epilepsy.
Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.
